0.7658 USD
+0.05 (+6.36%)
We assign a fundamental rating of 3 out of 10 to NMTC. NMTC was compared to 184 industry peers in the Health Care Equipment & Supplies industry. The financial health of NMTC is average, but there are quite some concerns on its profitability. NMTC is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
NMTC had negative earnings in the past year.
NMTC had a negative operating cash flow in the past year.
NMTC had negative earnings in each of the past 5 years.
NMTC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
NMTC's Return On Assets of -48.45% is on the low side compared to the rest of the industry. NMTC is outperformed by 65.76% of its industry peers.
The Return On Equity of NMTC (-65.16%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.45% | ||
| ROE | -65.16% | ||
| ROIC | N/A |
ROA(3y)-149.31%
ROA(5y)-171.96%
ROE(3y)-585.78%
ROE(5y)-513.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NMTC's Gross Margin of 70.14% is fine compared to the rest of the industry. NMTC outperforms 77.72% of its industry peers.
The Profit Margin and Operating Margin are not available for NMTC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.14% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NMTC has more shares outstanding
NMTC has more shares outstanding than it did 5 years ago.
NMTC has a worse debt/assets ratio than last year.
2.2 Solvency
NMTC has an Altman-Z score of -1.56. This is a bad value and indicates that NMTC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.56, NMTC is not doing good in the industry: 60.33% of the companies in the same industry are doing better.
NMTC has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
NMTC's Debt to Equity ratio of 0.13 is fine compared to the rest of the industry. NMTC outperforms 63.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.56 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
NMTC has a Current Ratio of 6.99. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.
NMTC has a better Current ratio (6.99) than 85.87% of its industry peers.
NMTC has a Quick Ratio of 5.66. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.
NMTC's Quick ratio of 5.66 is amongst the best of the industry. NMTC outperforms 84.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.99 | ||
| Quick Ratio | 5.66 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 69.40% over the past year.
Looking at the last year, NMTC shows a very strong growth in Revenue. The Revenue has grown by 142.96%.
The Revenue has been growing by 143.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)69.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)142.96%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%105.38%
3.2 Future
The Earnings Per Share is expected to grow by 19.40% on average over the next years. This is quite good.
Based on estimates for the next years, NMTC will show a very strong growth in Revenue. The Revenue will grow by 34.68% on average per year.
EPS Next Y73.81%
EPS Next 2Y27.24%
EPS Next 3Y19.4%
EPS Next 5YN/A
Revenue Next Year27.13%
Revenue Next 2Y26.81%
Revenue Next 3Y28.25%
Revenue Next 5Y34.68%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NMTC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NMTC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NMTC's earnings are expected to grow with 19.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.24%
EPS Next 3Y19.4%
5. Dividend
5.1 Amount
NMTC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:NMTC (12/24/2025, 1:30:01 PM)
0.7658
+0.05 (+6.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners33.58%
Inst Owner Change6.62%
Ins Owners4.17%
Ins Owner Change-0.63%
Market Cap38.29M
Revenue(TTM)9.63M
Net Income(TTM)-5.33M
Analysts85
Price Target2.27 (196.42%)
Short Float %0.12%
Short Ratio0.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.46%
Min EPS beat(2)23.75%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)47.24%
Min EPS beat(4)-34.8%
Max EPS beat(4)158.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-25.92%
Min Revenue beat(2)-43.22%
Max Revenue beat(2)-8.62%
Revenue beat(4)1
Avg Revenue beat(4)-21.92%
Min Revenue beat(4)-88.49%
Max Revenue beat(4)52.66%
Revenue beat(8)2
Avg Revenue beat(8)-19.9%
Revenue beat(12)4
Avg Revenue beat(12)-5.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)11.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)17.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.98 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.58 | ||
| P/tB | 4.61 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.19
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.45% | ||
| ROE | -65.16% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.14% | ||
| FCFM | N/A |
ROA(3y)-149.31%
ROA(5y)-171.96%
ROE(3y)-585.78%
ROE(5y)-513.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 40.74% | ||
| Cap/Sales | 1.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.99 | ||
| Quick Ratio | 5.66 | ||
| Altman-Z | -1.56 |
F-Score5
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)158.02%
Cap/Depr(5y)160.31%
Cap/Sales(3y)9.27%
Cap/Sales(5y)12.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y73.81%
EPS Next 2Y27.24%
EPS Next 3Y19.4%
EPS Next 5YN/A
Revenue 1Y (TTM)142.96%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%105.38%
Revenue Next Year27.13%
Revenue Next 2Y26.81%
Revenue Next 3Y28.25%
Revenue Next 5Y34.68%
EBIT growth 1Y53.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.69%
OCF growth 3YN/A
OCF growth 5YN/A
NEUROONE MEDICAL TECHNOLOGIE / NMTC FAQ
What is the fundamental rating for NMTC stock?
ChartMill assigns a fundamental rating of 3 / 10 to NMTC.
What is the valuation status for NMTC stock?
ChartMill assigns a valuation rating of 0 / 10 to NEUROONE MEDICAL TECHNOLOGIE (NMTC). This can be considered as Overvalued.
What is the profitability of NMTC stock?
NEUROONE MEDICAL TECHNOLOGIE (NMTC) has a profitability rating of 1 / 10.
What is the expected EPS growth for NEUROONE MEDICAL TECHNOLOGIE (NMTC) stock?
The Earnings per Share (EPS) of NEUROONE MEDICAL TECHNOLOGIE (NMTC) is expected to grow by 73.81% in the next year.